Daiichi Sankyo has been granted breakthrough status by the FDA for patritumab deruxtecan, a HER3-targeted antibody-drug conjugate (ADC) in clinical trials for lung cancer. The designation ...
AstraZeneca and Daiichi Sankyo have revealed new data from datopotamab deruxtecan in triple negative breast cancer (TNBC) – and although it’s from a small patient group results look impressive.
Hosted on MSN3mon
AZN, Daiichi Withdraw EU Filing for Dato-DXd in Nonsquamous NSCLCThe FDA has issued a complete response letter to Merck/Daiichi’s BLA seeking accelerated approval for patritumab deruxtecan in previously treated EGFR-mutated NSCLC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback